Trial: 202203028

A Phase 1, Open-label, Dose-escalation trial of CD33xCD3 Bispecific Antibody in Pediatric patients with Relapsed or Refractory Acute Myeloid Leukemia

Phase

I

Principal Investigator

Hayashi, Robert

Disease Site

Myeloid and Monocytic Leukemia

Learn more about this study at: clinicaltrials.gov